Biomedical Research

Objective: This study is to investigate the association of β-amyloid 1-42 (Aβ1-42), Cystatin C (Cys C), Uric Acid (UA) with Parkinson’s disease (PD).

Methods: A total of 108 PD patients and 108 healthy individuals were enrolled. The serum levels of Aβ1-42, Cys C and UA were measured. The Operating Characteristic Curve (ROC) was drawn, and then the Area Under the Curve (AUC), 95% Confidence Interval (CI), sensitivity and specificity were calculated.

Results: Serum Aβ1-42 and UA levels in PD patients were significantly lower than those in healthy controls. Serum Cys C level in PD patients was significantly higher. The AUC of Aβ1-42 was 0.644, 95% CI was 0.570~0.718, diagnostic sensitivity and specificity were 52.8% and 74.1% and the cut-off point was 0.912 μg/L. The AUC of UA was 0.633, 95% CI was 0.557~0.708, sensitivity and specificity were 65.7% and 64.8% and the cut-off point was 281 μmol/L. Serum UA in male PD patients was significantly higher than that in female PD patients. Serum Cys C in PD patients were significantly higher than that in healthy controls. Serum Aβ1-42 was negatively correlated with HY grade. Serum Cys C was positively correlated with HY grade. Serum UA was negatively correlated with HY classification, UPDRS score and the III scores.

Conclusion: Serum Aβ1-42 and UA may contribute to PD diagnosis. Cystatin C may be involved in the development of PD and be helpful in assessing the PD severity.

Author(s): Jing Lei, Jianhua Ma, Ruobing Liang, Xiaoning Zhang
Abstract | Full-Text | PDF

Share this